NSE · AUROPHARMA
Aurobindo Pharma Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3,177 Cr with net profit ₹724 Cr — a 22.77% net margin, versus 26.33% the period before.
Shareholding
As of 2026-09-30
- Promoter51.88%
- Public6.29%
- FII17.41%
- DII24.42%
2,33,737 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.63× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #7 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd.(this company) | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
AI analysis
AI-generated · google/gemini-2.5-flashAurobindo Pharma Ltd. operates with a market capitalization of Rs 90582 Cr. The company reported revenue of Rs 32345.58 Cr with a profit margin of 10.5%. The earnings per share (EPS) stands at Rs 61.09.
Positives
- +Revenue grew by 9.4% to Rs 32345.58 Cr.
- +Debt-to-equity ratio is 0.24, indicating low leverage.
- +Promoter holding is 51.88% as of Jun 2026.
Negatives
- −The trailing twelve months PE ratio is 98.34.
- −Return on equity (ROE) is 9.25%.
- −Return on capital employed (ROCE) is 11.76%.
- −Promoter pledge percentage is 13.75% of promoter holding as of Jun 2026.
- −The number of shareholders increased from 134259 in Sep 2016 to 239073 in Jun 2026.
Financial Performance
For the period ending Mar 2025, Aurobindo Pharma Ltd. reported revenue of Rs 32345.58 Cr, reflecting a revenue growth of 9.4%. Net profit was Rs 3485.88 Cr for the same period. Quarterly revenue for Mar 2026 was Rs 8853.34 Cr, with a net profit of Rs 921.26 Cr. However, quarterly revenue for Jun 2025 was Rs 7868.14 Cr, showing a decrease from the previous quarter.
Profitability & Returns
The company's profit margin stood at 10.5%. Return on equity (ROE) was 9.25%, and return on capital employed (ROCE) was 11.76%. The earnings per share (EPS) for the fiscal year ending Mar 2025 was Rs 59.81.
Balance Sheet
Aurobindo Pharma Ltd. has a debt-to-equity ratio of 0.24. The book value per share is Rs 652.39.
Ownership & Pledges
Public shareholding is 6.64%. The promoter pledge percentage is 13.75% of the total promoter holding as of Jun 2026.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.